Nuevolution, a leading small molecule lead discovery company based in Copenhagen, has teamed with key scientific advisors to assist the progression of its internal drug discovery programmes within inflammation and oncology.
In June 2012, Nuevolution announced the closing of a new financing round, and the plans to initiate internal drug discovery efforts. Since then, Nuevolution has prioritized more than 30 high-value challenging targets for screening, which has been initiated. The target prioritization and further programme decisions have been made in close collaboration with the newly appointed advisors.
Professor Sir Marc Feldmann, Kennedy Institute, UK, is a world-renowned scientist within immunology and a special interest in the fields of autoimmune diseases and the roles of cytokines. He is recipient of numerous honors and awards over the years and has pioneered the work on the development of antibodies against TNFa for the treatment of RA.
Professor Dr. Gordon B. Mills, MD Anderson Cancer Center, US, is a world leading scientist within oncology and professor and chair in the Department of Systems Biology in the Division of Cancer Medicine at the MD Anderson Cancer Center, where he holds the Olga Keith Wiess distinguished university chair in Cancer Medicine. Dr. Mills is co-director of the Sheikh Khalifa bin Zayed Al Nahyan Institute for Personalized Cancer Therapy and director Kleberg Center for Molecular Markers. He also serves as advisor for preclinical and clinical oncology studies supporting numerous pharmaceutical and biotechnology companies.
Dr. Alan Collis, formerly was with Novartis and Aventis, US, has 25 years of industry experience. He has a very strong track-record within chemistry, DMPK studies and pre-clinical candidate development. He has served as head of section within oncology at Novartis and as a central member of their Oncology and Exploratory Chemistry leadership team. At Aventis he served at their Review Board involved with recommendations from target selection through to phase IIb initiation within inflammation and CNS diseases.
”We are obviously delighted to receive support from such a strong and experienced advisory team to help us leverage our Chemetics technology platform and plan and promote our own pipeline” said Thomas Franch, CSO of Nuevolution. “We look forward to working with Marc, Gordon and Alan and we are confident that they will help accelerate our discovery projects and provide substantial value to our programmes.